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ABSTRACT 
 
Streptococcus pneumoniae is a major human pathogen that causes over 1.6 million deaths 
worldwide each year through such diseases as pneumonia, meningitis, and otitis media (1).  
Adherence of S. pneumoniae to the airway is essential for colonization which is a precursor to 
disease; however, adherence mechanisms are poorly understood.  We discovered a novel 
mechanism that involves the adherence of beta-galactosidase, BgaA (a sugar-cleaving enzyme) 
to the epithelial cell surface.  Preliminary studies suggest that the epithelial cell receptor for 
BgaA is a glycosphingolipid.  Asialo-GM1, a glycosphingolipid previously proposed as a 
receptor for S. pneumoniae, was tested as a possible receptor for BgaA; however, the addition of 
neither purified asialo-GM1 nor anti-asialo-GM1 was able to reduce adherence of S. pneumoniae 
to epithelial cells, indicating that asialo-GM1 is likely not a receptor for BgaA.  When 
demonstrating clinical relevance of this novel mechanism, some clinical isolates were found to 
be reduced in adherence after the addition of recombinant BgaA (rBgaA), whereas other clinical 
isolates were not.  Differences in adherence could be attributed to allelic diversity within the 
gene or differences in enzyme expression, among other possibilities.  To determine if allelic 
diversity may contribute to BgaA-mediated adherence, the gene was sequenced.  Predicted 
amino acid differences were found between two strains reduced in adherence upon the addition 
of rBgaA and two strains that were not, indicating that these differences could contribute to the 
ability of BgaA to act as an adhesin.  The BgaA alleles were exchanged between strains; 
however, these mutants did not show an exchange in phenotype, indicating that these sequence 
differences are not responsible for the ability of BgaA to act as an adhesin.  To determine if 
increased levels of BgaA expression contribute to adherence, beta-galactosidase activity was 
tested and used as an indicator of possible expression level differences.  Strains reduced in 
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adherence upon the addition of rBgaA had higher activity, suggesting increased expression of 
BgaA.  These findings will help to further characterize the BgaA-mediated mechanism of 
adherence which will help in understanding pneumococcal colonization. 
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INTRODUCTION 
 
Streptococcus pneumoniae is a major human pathogen that causes diseases ranging from otitis 
media to bacteremia and meningitis and is the most common bacterial cause of community 
acquired pneumoniae (10). S. pneumoniae is estimated to cause over 1.6 million deaths 
worldwide each year with more than 45,000 deaths occurring annually in the U.S. (24).  Acting 
as an opportunistic pathogen, S. pneumoniae is more likely to cause disease in young, elderly, or 
immuno-compromised individuals (7).  Despite the high levels of morbidity and mortality, S. 
pneumoniae generally colonizes the oropharynx or nasopharynx asymptomatically (33) and is 
usually cleared by the host; however, invasive disease can occur if bacteria spread beyond the 
upper airway to areas such as the lungs, blood, or meninges.  
 
Over 90 serotypes, as defined by capsule polysaccharide, of S. pneumoniae are known; however, 
most disease is caused by a small number of serotypes (27).  Two vaccines based on capsule 
polysaccharide are currently available.  Created in 1983, the first vaccine was composed of 
purified free polysaccharides derived from the capsule of 23 serotypes (8).  This vaccine, 
however, lacks the ability to induce immunological memory and is therefore limited in its 
efficacy (3).  In 2000, a conjugated vaccine linking capsular polysaccharide of seven 
pneumococcal serotypes to a protein carrier was introduced (2).  Able to elicit a memory 
response in young children (5), this vaccine has helped to decrease invasive disease and 
colonization due to capsular types included in the vaccine (17, 21, 26).  Despite the ability of the 
PCV7 to reduce disease caused by vaccine strains, colonization and disease caused by non-
vaccine strains has significantly increased in North American populations (17, 21) (11, 25).  This 
evidence indicates that efficacy of the PCV7 vaccine will likely decrease over time.  Another 
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conjugate vaccine containing up to 13 serotypes is in development to improve pneumococcal 
protection in adults and children (2); however, efficacy of this vaccine is likely to decrease over 
time, as well.  Similarly, pneumococcal strains have become increasingly resistant to antibiotics 
(9, 16).  Limited vaccine efficiency and increasing antimicrobial resistance indicate that research 
contributing to possible treatments and/or preventative measures is of importance. 
 
As previously stated, pneumococcal colonization is essential to cause disease.  Despite years of 
research, little is known about how S. pneumoniae establishes and maintains colonization.  
Adherence of the bacteria to the epithelial cell surface is known to play a role in colonization and 
several mechanisms have been already been identified (13).  Because adherence is an important 
step in colonization, S. pneumoniae is likely to use multiple mechanisms.  Our lab has identified 
a novel mechanism of adherence involving pneumococcal surface-associated exoglycosidases 
(terminal sugar-cleaving enzymes).  Pneumococcal exoglycosidases are presumed to cleave 
sugar structures that decorate the epithelial cell surface in the human airway.  The released 
sugars are proposed to be used as a carbon source for pneumococcal metabolism (6).  Cleavage 
of these sugars has also been proposed to help the pathogen move through the thick mucin layer 
(28, 36) or help to reveal receptors for adherence (30, 31).  NanA, a pneumococcal cell surface-
associated exoglycosidase that cleaves terminal sialic acid, has been proposed to reveal a 
receptor on the epithelial cell surface.  Tong et al. 2002 (31) demonstrated increased 
pneumococcal adherence to neuraminidase-treated chinchilla tracheas.  Similarly, Barthelson et 
al.1998 (4) demonstrated that adherence to epithelial cells was inhibited by the addition of 
sialyated glycoconjugates.  S. pneumoniae encodes other surface-associated glycosidases that 
could further modify host glycoconjugates.  We recently demonstrated that S. pneumoniae can 
2 
 
sequentially deglycosylate N-linked glycans through the activity of NanA, β-galactosidase, 
BgaA, and N-acetylglucosaminidase, StrH (19).  The ability of S. pneumoniae to sequentially 
deglycosylate host glycoconjugates suggests that other exoglycosidases could be working in 
conjunction with NanA to reveal a receptor for pneumococcal adherence on the epithelial cell 
surface.  While investigating the role of sequential deglycosylation in revealing receptors, NanA 
and BgaA, but not StrH, were determined to be necessary for pneumococcal adherence (19).  
This evidence suggested that NanA and BgaA act sequentially to reveal a receptor.  Adherence 
of a nanA mutant to epithelial cells was complemented by the addition of exogenous 
neuraminidase; however, adherence of a bgaA mutant to epithelial cells could not complemented 
by the addition of recombinant BgaA (rBgaA) (Unpublished data).  This evidence suggests that 
NanA cleaves terminal sialic acid, revealing a receptor to which BgaA binds.  Evidence 
supporting this hypothesis includes:  The addition of rBgaA reduced the binding of wildtype 
strains to human epithelial cells and the adherence of rBgaA coated fluorosphere beads to 
epithelial cells indicated that BgaA can bind directly to epithelial cells.  Lastly, a BgaA active 
site mutant was constructed and tested in adherence and was not significantly reduced in 
adherence as compared to wild-type, further demonstrating that the role of BgaA in adherence is 
independent of enzymatic activity (Unpublished data).   
 
BgaA is the second-largest protein encoded in the pneumococcal genome and is approximately 
twice the size of other β-galactosidases at 2228 amino acids, suggesting that BgaA may have a 
second function (23).  BgaA is predicted to be secreted and attached to the pneumococcal surface 
in a sortase-dependent manner (18) and other than the cell-wall anchoring motif, the function of 
the C-terminal region remains unknown.  Bifidobacterium bifidum and S. gordonii express β-
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galactosidases of similar length to S. pneumoniae (12, 32) and although the role of these proteins 
in adherence has not been tested, it is possible that BgaA belongs to a family of adhesins. 
 
The host cell receptor for BgaA remains unknown.  The contribution of NanA to this mechanism 
suggests that the receptor is a glycoconjugate (a sugar structure attached to another molecule), 
such as a glycoprotein or glycosphingolipid.  To determine of BgaA binds to a glycoprotein, 
adherence of S. pneumoniae to protease-treated human epithelial cells (to cleave possible 
glycoprotein receptors) was measured.  Bacterial adherence was significantly higher to protease 
treated epithelial cells as compared to non-protease treated epithelial cells, indicating that the 
receptor is not a glycoprotein cleaved by protease.  In fact, the increase in bacterial adherence to 
protease-treated epithelial cells suggests that protease treatment helped to further reveal an 
epithelial cell receptor for S. pneumoniae.  This data indicate that the receptor could instead be a 
glycosphingolipid.  In investigation of bacterial adherence to the carbohydrate sequence 
GalNAcβ1-4Gal found in some glycolipids, Krivan et al. demonstrated the ability of S. 
pneumoniae to bind to the glycosphingolipid, asialo-GM1 (20).  The galactose residue in asialo-
GM1 may help mediate the binding of BgaA, which has enzymatic specificity for terminal 
galactose. 
 
In demonstrating clinical relevance, the adherence of some recent clinical isolates obtained from 
Nationwide Children’s Hospital to epithelial cells were found to be blocked by the addition of 
rBgaA whereas some other clinical isolates were not (Figure 1).  The reasons for differences in 
the contribution of BgaA to adherence could be accounted for by many reasons including 
possible amino acid sequence differences within the BgaA allele amongst the strains, possible 
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BgaA expression level differences, possible differences in capsular expression, or the 
distribution of other adherence mechanisms amongst the strains.  Amino acid sequence 
differences may contribute to differences in the contribution of BgaA to adherence if these 
differences affect binding of the receptor.  Or, differences in contribution of BgaA to adherence 
could result from differences in the level of protein expression on the bacterial cell surface, as a 
higher expression of BgaA could mean that more protein is available to act as an adhesin.  
Similarly, differences in capsular expression could account for differences in the contribution of 
BgaA to adherence as a thinner capsule could mean that more protein is available to act as an 
adhesin.  Lastly, because adherence is a preliminary step to colonization and pneumococci are 
diverse, different strains could encode different redundant mechanisms of adherence.   
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Figure 1.  Demonstration that the BgaA-mediated mechanism is relevant in vivo, however differences in the ability of 
BgaA to act as an adhesion differ among recent clinical isolates.  Adherence of strains (O.D. 600 nm = 0.6) to D562 cells 
over 60 min is expressed as a percentage of parental strain adherence. All wells were pretreated for 30 min with 0.01 U of 
purified C. perfringens neuraminidase per 1.9 cm2 of well surface area. Where indicated, 0.433 pm of rBgaA was added to 
the inoculum. Values are the mean of at least three independent experiments ±SD.  Statistical significance was determined 
using Student’s t-test.  
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Despite the importance of adherence to pneumococcal colonization and disease, most 
mechanisms remain unknown.  We have discovered a novel mechanism of adherence involving 
the pneumococcal surface-associated exoglycosidases, NanA and BgaA.  The aim of this study 
was to further characterize the BgaA-mediated mechanism of adherence so as to better 
understand pneumococcal adherence and help in the ability to develop more effective strategies 
to reduce pneumococcal colonization and disease. 
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METHODS 
Bacterial strains, culture, media, and chemicals.  Wild-type and genetically altered strains of 
S. pneumoniae and the recent clinical isolates used in this study are described in Table 1.  Broth 
cultures were grown at 37°C in Todd-Hewitt broth (Becton, Dickenson, and Co., Sparks, MD) 
supplemented with 0.2% w/v yeast extract (Becton, Dickenson, and Co.) (THY).  C media with 
5% yeast extract (C+Y) pH 8 was used for transformations (22).  S. pneumoniae was also grown 
at 37°C and 5 % CO2 overnight on tryptic soy (TS) (Becton, Dickenson, and Co.) plates with 1.5 
% agar that were spread with 5000 U catalase (Worthington Biochemical Corporation, 
Lakewood, NJ) prior to plating bacteria.  Where appropriate, strains were selected for on TS 
plates that contained either streptomycin (200 µg/mL) or kanamycin (500 µg/mL) as appropriate.  
Detroit 562 cells (ATTC CCL-185), a human pharyngeal carcinoma cell line, were grown in 
minimal essential media supplemented with 10 % fetal bovine serum, 1.1 % sodium pyruvate, 
110,000 u/ml penicillin, and 110 mg/ml streptomycin at 5 % CO2.  Unless otherwise indicated, 
all chemicals, substrates, and enzymes were purchased from Sigma Chemicals (St. Louis, MO).  
 
Genomic DNA Preparation.  All genomic DNA was prepared as previously described (35).  
Briefly, 10 mL of Optical Density at 600 nm (OD600) = 0.8 culture was centrifuged and re-
suspended in 500 µL 50 mM ethylenediaminetetraacetic acid (EDTA)/10 mL 
tris(hydroxymethyl)aminomethane (TRIS) (pH 8.0).  Bacteria were incubated at 37°C with 20 
µL 10 mg/mL lysozyme for 30 minutes (min) and subsequently with 30 µL 10 mg/mL proteinase 
K for an additional 30 min.  40 µL of 20 % v/v N-lauroyl sarcosine was added and mixed by 
inversion.  After 10 min bacteria were subjected to two rounds of extraction with an equal 
volume of phenol/chloroform/isoamyl alcohol (Fisher Scientific, Pittsburgh, PA) and a final 
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extraction with an equal volume of chloroform.  DNA was isolated from the aqueous phase and 
precipitated with 100 % cold ethanol.  When necessary, the addition of 3 mM sodium acetate 
(pH 5.2) at 1/10 the sample volume was used to aid precipitation.  The pellet was washed with 70 
% v/v ethanol, vacuum dried, and re-suspended in 50 µL dH20. 
 
Polymerase Chain Reaction.  All reactions (50 µL unless otherwise noted) were carried out in 
0.2 mL flat cap PCR tubes.  Master-mixes containing all reagents except the DNA template were 
pre-mixed and aliquoted into PCR tubes; DNA template was added individually to each reaction.  
H20 rather than DNA template served as a negative control.  When possible, positive controls 
were included.   
Reactions using the high-fidelity polymerase, Pfx50 (Invitrogen, Carlsbad, CA).  A high 
fidelity polymerase was used in the construction of the desired construct for transformation into 
S. pneumoniae.  To identify optimal amounts of DNA, neat, 1:5 and 1:10 dilutions of DNA were 
included until one was identified as most suitable.  Primers were generally used at 0.4 µg/µL per 
manufacturer’s instructions; however, if no product was obtained, a primer concentration of 1 
µg/µL was used.  Standard 50 µL reaction: 
Reagent Amount (µL) 
10x Pfx50 PCR Buffer 5 
10x dNTP (2 mM each) 0.75 
MgSO4  0.5 
Primer 1 (0.4 or 1 µg/µL) 0.2 
Primer 2 (0.4 or 1 µg/µL) 0.2 
Pfx50 polymerase 1 
Chromosomal DNA template 0.3 
De-ionized H20 To 50 
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Thermocycling Parameters in the BioRad MyCycler™ Thermal Cycler 
95°C Denature 4 min 
 
95°C Denature 1 min 
≥60°C Annealing 1-2 min 
72°C Elongation 1 min/kb 
 
72°C Polishing 1 min 
4°C   
   
 The annealing temperature should be determined for each reaction by estimating the 
temperature at which 50 % of the primer is dissociated (Tm) and using an annealing temperature 
2°C less than that of the lowest primer.  Estimation of primer Tm can be performed by counting 
each cytosine or guanine as 4°C and each adenine or thymine as 2°C. 
Reactions using Choice™ Taq DNA Polymerase (Denville, Metuchen, NJ).  When 
amplifying products for sequencing or screening potential mutants with flanking primers, 
standard Taq polymerase was used.  Standard 50 µL reaction:  
Reagent Amount (µL) 
10x PCR Buffer containing 15 mM MgCl2  
 
5 
10x dNTP (10 mM each) 0.75 
MgCl2 0.5 
Primer 1 (1 µg/µL) 0.2 
Primer 2 (1 µg/µL) 0.2 
Taq polymerase 0.2 
DNA template 0.3 
De-ionized H20 To 50 
Thermocycling Parameters in the BioRad MyCycler™ Thermal Cycler 
95°C Denature 4min 
 
95°C Denature 1min 
55 ± 5°C Annealing 1-2min 
72°C Elongation 1min/kb 
 
72°C Polishing 1min 
4°C   
1x 
 
 
30x 
 
 
1x 
HOLD 
1x 
 
 
30x 
 
 
1x 
HOLD 
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 Sequencing Reactions with Big Dye® Terminator reaction mixture.  Sequencing was 
conducted using the PCR products obtained for segments of the bgaA region of clinical isolates 
and from reactions run with flanking primers for exchanged bgaA regions.  Standard 10 µL 
sequencing reaction with Big Dye Terminator version 3.1: 
Reagent Amount (µL) 
DMSO 0.5 
DNA 45 ng* 
Primer 1.6  pmol (1 µL of 1:100 dilution) 
Big Dye 2 
5x Buffer 1 
De-ionized H20 To 10 
 
*Amount of a DNA sample can be estimated by comparing the relative intensity of the template 
band to a band with a known amount of DNA in the 1 kb ladder when run on an agarose gel. 
Sequencing Thermocycling Parameters in the BioRad MyCycler™ 
   
96°C Denature 10 sec 
50°C Annealing 5 sec 
60°C Elongation 4 min 
 
4°C 
  
   
   
   
 
 
25x 
 
 
HOLD
Electrophoresis of DNA on a 1 % agarose gel.  Agarose gels were prepared by dissolving 
agarose in 1xTAE to 1 % w/v.  Ethidium bromide (final concentration = 0.025 µg/mL) was 
added directly to the melted agarose.  To visualize chromosomal DNA, 2 µL of DNA was mixed 
with 3 µL dH2O and 2 µL loading dye.  To visualize PCR products (unpurified or purified with 
the QiaQuick PCR purification kit (Qiagen)) mix 2 µL PCR product with 3 µL dH2O and 2 µL 
of loading dye.  Samples were electrophoresed horizontally at 110 Volts in gels submerged in 
1xTAE.  DNA was visualized by UV-transillumination using Kodak Molecular Imaging 
Software and photographed with a Kodak IS2000MM camera. 
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 Sequence analysis.  Upstream and downstream sequences were compared using Lasergene 
SeqMan software.  If a discrepancy was found between sequencing reactions, the 
chromatographic output was analyzed to determine the correct base.  Sequence comparisons 
were performed using Lasergene MegAlign software. 
 
Transformations.  Strains were grown in C+Y medium pH 8 at 37°C to an OD600 = 0.15.  50 
µL of bacterial culture was transferred to 950 µL aliquots of C+Y pH 8 media warmed to 30°C.  
Bacterial competence was induced by the addition of stimulating peptide, 2 µL 1 mg/mL CSP1 
and 10 µL 10 mM CaCl2 and incubated for 10 min at 30°C.  After the addition of DNA, cultures 
were incubated for 40 min at 30°C and then 90 min at 37°C. 
 
Genetic exchange of bgaA region.  This was performed using a Janus Cassette selection system 
(29).  Construction of a mutant strain using this system requires two rounds of transformation.  
The first round introduces a Janus rpsL cassette, which inserts kanamycin resistance, into the 
genomes of a streptomycin resistant (SmR) R6 and NCH39 S. pneumoniae strains, replacing the 
area of interest.  The Janus construct used to transform our S. pneumoniae strains was engineered 
using a variation on the splicing by overlap extension (SOE) by PCR process (14).  In order to 
minimize PCR generated errors, all PCRs were conducted using a high-fidelity proofreading 
polymerase (Pfx50).  All PCR products were purified and concentrated using a PCR purification 
kit.  DNA fragments flanking the bgaA region were amplified using primers E.1 and E.2 
(upstream fragment) and E.3 and E.4 (downstream fragment) (Table 2).  Each primer pair 
contained one hybrid primer such that sequences complementary to the Janus cassette primers 
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were introduced at the 3’ end of the upstream DNA fragment and 5’ end of the downstream 
DNA fragment.  These PCR products were sequentially joined to the Janus cassette PCR product 
(primers J.1 and J.2) using SOE.  Transformants were selected for on kanamycin, and their 
antibiotic susceptibility phenotype was subsequently confirmed as kanamycin resistant (KmR) 
and SmS  Using chromosomal DNA, the second round of transformation replaced the Janus 
cassette in R6 with DNA from the bgaA region of NCH39 and the Janus cassette in NCH39 with 
DNA from the bgaA region of R6.  Unmarked mutants were selected for on streptomycin, and 
their antibiotic susceptibility phenotype was subsequently confirmed as KmS and SmR.  
Generation of the unmarked mutants was confirmed by PCR with primers flanking the construct 
(E.5 and E.6) and sequencing. 
 
Adherence of S. pneumoniae to human epithelial cells.  Strains were grown in THY medium 
at 37°C to an OD600 = 0.6 and diluted 25 fold in minimal essential media (Invitrogen) 
supplemented with 10 % fetal bovin serum (Invitrogen) and 1.1 % sodium pyruvate (Mediatech, 
Inc., Manassas, VA).  80 µL of the bacterial innoculum was added per 1.9 cm2 of well surface.  
Epithelial cells were pretreated for 30 min with 0.01 U of purified Clostridium perfringens 
neuraminidase per 1.9 cm2 of well surface area.  (C. perfringens neuraminidase has the same 
cleavage specificity as pneumococcal neuraminidase, NanA.)  Neuraminidase was removed by 
three washes in phosphate buffer solution (PBS).  The bacteria were allowed to adhere at 37°C 
and 5 % CO2 for 60 min.  Non-adherent bacteria were removed by five washes with PBS.  
Epithelial cells and adherent bacteria were lifted with 200 µL 0.25 % trypsin/1mM EDTA 
(Invitrogen), vortexed and maintained at 4°C.  Bacteria were then enumerated by serial dilutions 
and plating of either 10 µl or 100 µl aliquots in triplicate on TS plates.  The percentage 
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adherence of all strains was calculated as the proportion of the inoculums that adhered to 
epithelial cells.  Adherence of the untreated wild-type and parental strains was adjusted to 100 % 
and the adherence of other conditions or strains was made relative to this value.  Averages of at 
least three independent experiments performed in triplicate were used for statistical analysis.  
Assays in which the adherence of clinical isolates was reduced by the addition of recombinant 
BgaA (rBgaA), 4.33 pm of BgaA per 1.9 cm2 of well surface area was added to bacterial 
inoculums.  Assays in which adherence of R6 was blocked with anti-asialo-GM1, D562 cells 
were incubated with 100 µL of 0, 3.7, or 10 mg/ml anti-asialo-GM1 polyclonal rabbit antibody 
for 60 min after pretreatment with purified neuraminidase and prior to inoculation.  Assays in 
which adherence of R6 was blocked with purified GM1, 10 ng, 100 ng, 10 µg, or 100 µg of 
purified GM1 was added per 80 µL bacterial inoculum and incubated on ice for 30 min prior to 
being added to the epithelial cells.   
 
Beta-galactosidase activity assays.  Strains were grown in THY medium at 37°C to OD600 = 
0.6.  1 mL each of total culture was placed in a microcentrifuge tube and 3 µL toluene was 
added.  After being vortexed for 30-40 sec, the tubes were rotated at 37°C and 5 % CO2  for 15 
min.  The tubes were then left uncapped in the fume hood for 20 min to ensure evaporation of the 
toluene.  200 µL of 4 mg/mL o-nitrophenyl-β-D-galactopyranoside (ONPG- the colorimetric 
substrate) dissolved in 0.1 M sodium phosphate buffer solution was added to each tube which 
were then placed back in the rotator at 37°C and 5 % CO2 for 60 min.  The reaction was stopped 
by the addition of 500 µL 1 M sodium carbonate.  The tubes were centrifuged and the 
absorbance of their supernatant measured at 420 nm by the BioTek Synergy HT plate reader.  
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The activity of BgaA, as expressed in Miller units, can be found by using the following equation:  
(100 x OD420)/(t x V x OD600)  t= 60 min  V=1 mL.   
 
Statistical analysis.  Adherence assays and β-galactosidase activity assays were run in triplicate 
on three independent occasions.  Media blanks were subtracted from activity assay data.  All 
presented data was analyzed using Student’s t-tests.   
 
Table 1. Strains used in this study. 
Strain Name Serotype Characteristics/genotype Source or Reference 
R6 UN Lab strain Ianneli et al. (1999) (15) 
R6∆bgaA UN ∆bgaA Unpublished data 
NCH18 22F Clinical Isolate Nationwide Children’s 
Hospital 
NCH34 35F Clinical Isolate Nationwide Children’s 
Hospital 
NCH39 35F Clinical Isolate Nationwide Children’s 
Hospital 
R6SmR  
  
UN Lys56→Thr in RpsL conferring SmR This study 
NCH39SmR 35F Lys56→Thr in RpsL conferring SmR This study 
R6bgaANCH39 UN Contains bgaA of NCH39 This study 
NCH39bgaAR6 35F Contains bgaA of R6 This study 
a. UN indicates unencapsulated 
b. SmR indicates streptomycin resistant 
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Table 2. Primers used in this study. 
 
Group Number 5'→3' Sequence 
bgaA: sequencing S.1 AGTACGCAGCAAAAGCAAAATAAT 
S.2 TAGATGCGATTTTAGAAGTTG 
S.3 CAGAGTGGGCAGTAAGGGTGAAT 
S.4 CCAGCGGCAGTTCGTCTTA 
S.5 ATTGGCTGGTTGGTTATTGTAGGA 
S.6 TTTACGCTCCATACGCCATCTCAT 
S.7 TCAAACTACCAAGCCTACGA 
S.8 GAATGTCAGGCGCTTTTATC 
S.9 GCGCAATCCATCCGTCCTGT 
S.10 CAAATCCAAGCGACCCAG 
S.11 GCGGCAGCCAAACAAGGAC 
S.12 GTTTGTCCTTGTTTGGCTGCCGC 
S.13 CTAATCAATTCGTACAAGGCAGG 
S.14 GGCTGAATAAAGATGCTCGCACGC 
S.15 CTGAGAAGACAGTTGCTGCTG 
S.16 CAGTTGACTAAGGAAAAACCAG 
S.17 CCTGCTGCTACTGCTGCTTG 
S.18 TGGCGTCTACATGGATTCTCAAGT 
S.19 TCACCAATATAGTCCGTACCT 
S.20 CACCTGAAATGCCTACCACTGTT 
S.21 GGATGTTGATAAGACTCGCTATG 
S.22 GTAACTACTAATCCTGCACT 
Janus J.1 CGTTTGATTTTTAATGGATAATG 
J.2 GGGCCCCTTTCCTTATGCTT 
bgaA: exchange E.1 ATTCGTAAGTTTGCTGTGGGAG 
E.2 CATTATCCATTAAAAATCAAACGTTTAGCATCTTCCTTGAGCGG1 
E.3 AAGCATAAGGAAAGGGGCCCTACAAGAAGATCTTCCAAAACTC2 
E.4 GGTCTTTAATGATAAAGAAGGTAT 
E.5 AAGGCCATTGGAATCGG 
E.6 TATTTAGGACAAGAGTTTTTC 
 
a. Accession number AE007374 for all except Primer J.1- AY334019 and Primer J.2- AE005672 
b. Underline indicates reverse complement of Primer J.1(1) and J.2(2) 
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RESULTS 
 
Data suggest that BgaA does not bind to asialo-GM1. 
Previous investigation into possible epithelial cell receptors indicates that the receptor is likely a 
glycoconjugate, and more specifically a glycosphingolipid.  The glycosphingolipid, asialo-GM1 
has previously been proposed as a receptor for S. pneumoniae (20).  To determine if asialo-GM1 
is the epithelial cell receptor for BgaA, two methods were used.  In the first set of experiments, 
10 ng, 100 ng, 10 µL and 100 µL of purified asialo-GM1 was incubated with bacterial inoculums 
before they were tested in adherence to neuraminidase-treated epithelial cells.  If asialo-GM1 
binds BgaA, the purified asialo-GM1 should decrease the availability of BgaA on the bacterial 
cell surface and would presumably reduce the adherence of S. pneumoniae to epithelial cells.  
Similarly, in the second set of experiments, neuraminidase-treated epithelial cells were pretreated 
with 3.7 and 10 mg/mL of the rabbit polyclonal antibody, anti-asialo-GM1, which binds to and 
blocks asialo-GM1.  If asialo-GM1 is the receptor for BgaA, a reduction in adherence of the 
bacteria to the pretreated epithelial cells should occur.  Neither the addition of purified GM1 
(Figure 2) or the pretreatment of epithelial cells with anti-asialo-GM1 (Figure 3) significantly 
reduced the adherence of R6 to epithelial cells, indicating that asialo-GM1 is likely not a receptor 
for BgaA.  Knowledge of the binding site on the bgaA allele would be helpful in determining 
other possible receptors for BgaA.  Amino acid sequence differences could contribute to binding 
site variability which may account for the differences in the ability of BgaA to act as an adhesin 
for some recent clinical isolates.  Therefore, investigation into allelic variation among the bgaA 
alleles of clinical isolates could prove beneficial.   
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Figure 2.  The addition of purified asialo-GM1 does not significantly reduce adherence of R6 to epithelial cells.  
Adherence of strains (O.D. 600 nm = 0.6) to D562 cells over 60 min is expressed as a percentage of parental 
strain adherence. All wells were pretreated for 30 min with 0.01 U of purified C. perfringens neuraminidase per 
1.9 cm2 of well surface area. Where indicated, bacteria were incubated with purified asialo-GM1 for 30 min on 
ice. Values are the mean of at three independent experiments ±SD.  
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Figure 3.  Anti-asialo-GM1 does not significantly reduce adherence of R6 to epithelial cells.  Adherence 
of strains (O.D. 600 nm = 0.6) to D562 cells over 60 min is expressed as a percentage of parental strain 
adherence. All wells were pretreated for 30 min with 0.01 U of purified C. perfringens neuraminidase per 
1.9 cm2 of well surface area. Where indicated, wells were pretreated for 60 min at 37ºC with anti-asialo-
GM1 polyclonal rabbit antibody. Values are the mean of at three independent experiments ±SD.  
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Differences in the contribution of BgaA to adherence is most likely not due to allelic 
variation. 
 
To investigate possible allelic variation among isolates used to demonstrate clinical relevance, 
the bgaA allele of NCH18, NCH34, and NCH39 was sequenced and compared with the known 
sequence for the unencapsulated lab strain, R6.  Amino acid variation between strains range from 
0.9-1.9 %.  These differences exist between strains that were reduced in adherence with the 
addition of rBgaA (R6 and NCH18) and those that were not (NCH34 and NCH39).  The 
differences are located near the C-terminal region between amino acid 1760 and 2192.  Most 
notably, R6 and NCH18 lack five amino acids found within NCH34 and NCH39 (2050-2055).  
The presence of conserved amino acid differences supports the hypothesis that the contribution 
of BgaA to adherence could be determined by allelic variation among strains. 
 
The bgaA allele was exchanged between R6 and NCH39 by transformation with chromosomal 
DNA as a means to test this hypothesis.  The NCH bgaA allele was transformed into the R6 
background thereby creating R6bgaANCH39 and the R6 bgaA allele was transformed into the 
NCH39 background thereby creating NCH39bgaAR6.  A change in adherence phenotype for 
these strains would support the hypothesis.  If R6bgaANCH39 is not reduced in adherence to 
epithelial cells after the addition of rBgaA like the parental strain R6 and NCH39bgaAR6 is 
reduced in adherence to epithelial cells after the addition of rBgaA unlike the parental strain 
NCH39 then this would support the hypothesis that these allelic differences account for 
differences in the ability of BgaA to act as an adhesin.  Similarly, a reduction in adherence of 
R6bgaANCH39 without the addition of rBgaA would also support this hypothesis, as the allele 
would be unable to mediate adherence.  However, testing these strains in adherence to epithelial 
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cells after the addition of rBgaA resulted in data that does not support this hypothesis.  Neither 
strain showed an exchange in phenotype as adherence of the mutants was not significantly 
different and the ability to reduce adherence with rBgaA was the same as parental strains (Figure 
4).  This data suggest that the amino acid differences that exist between the bgaA alleles of 
strains do not account for differences in the ability of BgaA to act as an adhesin.  Other reasons 
must therefore account for differences in the contribution of BgaA to adherence of clinical 
isolates to epithelial cells, such as protein expression level differences. 
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Figure 4.  Demonstration that the exchange bgaA alleles does not change the adherence phenotype of R6 or NCH39.  Adherence of 
strains (O.D. 600 nm = 0.6) to D562 cells over 60 min is expressed as a percentage of parental strain adherence. All wells were 
pretreated for 30 min with 0.01 U of purified C. perfringens neuraminidase per 1.9 cm2 of well surface area. Where indicated, 0.433 
pm of rBgaA was added to the inoculum. Values are the mean of at least three independent experiments ±SD.  Statistical significance 
was determined using Student’s t-test.  
 
 
 
Differences in BgaA expression may affect the contribution of BgaA to adherence. 
 
To investigate whether possible protein expression level differences affect the contribution of 
BgaA to adherence, β-galactosidase assays were performed using the clinical isolates tested in 
adherence.  If expression levels do affect the BgaA-mediated mechanism of adherence, R6 and 
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NCH18 which were reduced in adherence after the addition of rBgaA would have higher 
expression (helping mediate adherence) and would therefore likely have higher enzymatic 
activity than NCH34 and NCH39 which were not reduced in adherence after the addition of 
rBgaA.  Data support this hypothesis as R6 and NCH18 were found to have statistically 
significant higher β-galactosidase activity than NCH34 and NCH39 (Figure 5).  Activity assays 
are merely an indication that there may be differences in protein expression levels and further 
investigation is required to fully support this hypothesis.  R6bgaANCH39 and NCH39bgaAR6 
were also tested for β-galactosidase activity levels as a means to determine if the changes 
introduced in the bgaA alleles of the strains affected the activity of BgaA.  Both strains were 
found to have similar activity to the respective parental strains, indicating that the changes 
introduced did not dramatically affect the enzymatic function of BgaA (Figure 6). 
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Figure 5.  R6 and NCH18 have significantly higher β-galactosidase activity than NCH34 and 
NCH39.  Strains were grown in THY broth (O.D. 600 nm = 0.6). Beta-galactosidase activity was 
determined using the colorimetric substrate O-Nitrophenyl beta-D-galactopyranoside. A media 
alone control was subtracted from all data. Values are the mean of three independent experiments 
±SD. Statistical significance was determined using Student’s t-test.  
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Figure 6.  R6SmR and R6bgaANCH39 have significantly higher β-galactosidase activity than NCH39SmR and 
NCH39bgaAR6.  Strains were grown in THY broth (O.D. 600 nm = 0.6). Beta-galactosidase activity was 
determined using the colorimetric substrate O-Nitrophenyl beta-D-galactopyranoside. A media alone control was 
subtracted from all data. Values are the mean of three independent experiments ±SD.  
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DISCUSSION 
The findings of this study help to further characterize this novel BgaA-mediated mechanism of 
adherence.  Previous studies have determined that the receptor for BgaA is most likely a 
glycoconjugate as NanA acts to cleave sialic acid thereby revealing a receptor to which BgaA 
binds.  Protease treatment resulted in an increase in adherence of R6 to epithelial cells 
determining that the receptor for BgaA is not a glycoprotein that can be cleaved by protease.  
The protease could be acting to further reveal a receptor for S. pneumoniae which could account 
for the observed increase in adherence.  Although not all glycoproteins can be discounted, this 
data indicates that the epithelial cell receptor for BgaA is likely a glycosphingolipid.  Asialo-
GM1 has previously been proposed a receptor for S. pneumoniae (20).  Our studies, however, 
show that this glycosphingolipid is most likely not the epithelial cell receptor for BgaA as R6 
was not reduced in adherence after the addition of either purified GM1 or anti-asialo-GM1 which 
would serve to block the possible receptor.  Together this data suggest that the receptor for BgaA 
is most likely a glycosphingolipid, but not asialo-GM1.  Further investigation may help elucidate 
a possible receptor for BgaA. 
 
As previous studies have demonstrated that BgaA contributes to the adherence of only some 
clinical isolates, investigating reasons for these differences may help to give insight into the 
BgaA-epithelial cell interaction including the identification of the possible binding site of BgaA 
and the discovery of a possible receptor.  Allelic variation of bgaA was found between strains 
that were reduced in adherence after the addition rBgaA and those that were not.  These 
differences are located at the C-terminal, a region of unknown function that may contain the 
binding site.  The exchange of bgaA alleles between R6 and NCH39 was found to have no affect 
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on the contribution of BgaA to adherence as R6bgaANCH39 and NCH39bgaAR6 had a similar 
adherence phenotype to the respective parental strains.  Because chromosomal DNA was used 
for transformation, some DNA outside of bgaA may have also been exchanged.  More time 
would allow for further investigation into where this exchange occurred; however, no changes 
made to the genome of either strain changed adherence phenotype and therefore differences in 
bgaA are most likely not responsible for the difference in contribution of BgaA to adherence.   
 
Despite these findings, possible differences in the level of protein expression could account for 
the difference in the ability of BgaA to act as an adhesin.  In investigation, R6 and NCH18 were 
found to have higher β-galactosidase activity than NCH34 and NCH39 which could indicate that 
BgaA expression level differences exist between clinical isolates and that a higher expression 
level may help to mediate adherence.  R6bgaANCH39 and NCH39bgaAR6 also showed no 
change in β-galactosidase indicating that the introduced amino acid changes did not significantly 
change the enzymatic activity of BgaA for each strain and that the difference in contribution of 
BgaA to adherence may be due to BgaA expression level differences.  This hypothesis requires 
further investigation using Western blotting or real time-reverse transcriptase PCR as activity 
levels only suggest possible differences in expression level.   
 
Capsule expression could also play a role in the contribution of BgaA to adherence, as a reduced 
amount of capsule correlates with an increase in colonization (34) which may be due to increased 
exposure of bacterial adhesins.  Ultimatley, the distribution of other adherence mechanisms 
could affect differences in the contribution of BgaA to adherence among clinical isolates.  Given 
the importance of adherence to colonization, multiple redundant mechanisms of adherence are 
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likely, all of which may contribute differently to adherence as is seen among the tested clinical 
isolates.  The role of BgaA in adherence is novel and relevant in recent clinical isolates, 
however, more investigation is required for further characterization of this mechanism and 
understanding of how knowledge of this mechanism can aid in the development of preventative 
measure for pneumococcal adherence and colonization.   
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